By Patrick Wingrove LONDON, Oct 15 (Reuters) - AstraZeneca has teamed up with artificial intelligence biotech company insitro ...

TDB will provide Rs 86 crore to Peptris Technologies for a Rs 172-crore project to advance four AI-discovered experimental ...

Can AI drug discovery stocks become the next NVIDIA?A thorough comparison of the future potential and financial risks of RXRX ...

Partnerships, licensing, capacity expansion, AI integration, thermostable formulations and decentralized manufacturing are key strategies for faster development and new revenue streams.Dublin, Oct. 15 ...

On October 15, 2026, there was a major development for the AI drug discovery company Recursion Pharmaceuticals (NASDAQ: RXRX).In this video, we will provide a thorough analysis of the clinical trial ...

The drugmaker will pay AI therapeutics company Insitro $40 million upfront and up to $1.46 billion subject to meeting targets ...

Detailed analyses of ligand choice, linkage vector and linker length enabled the development of bitopic inhibitors of ABL1 and EGFR kinases, including an ABL1 inhibitor with enhanced activity against ...

Indian scientists and biopharmaceutical firms are using artificial intelligence to identify promising drug candidates faster ...

AstraZeneca has entered into a strategic drug discovery collaboration and licensing agreement with insitro to use artificial intelligence to identify new drug targets and develop potential treatments ...

India’s Drug Market Grows 17.1% in September 2026 as Global Pharma Companies Accelerate Innovation, Capacity Expansion and ...

AstraZeneca will use insitro’s AI platform to identify potential drug targets for MASH and cardiomyopathies, drawing on its ...

Holbrook most recently led cardiovascular, renal and hepatic disease and in vitro discovery platforms at Novo Nordisk; she ...